Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Raetz

Showing results (31-40 of 69) with videos related to

Pageof 7
Sort By:
Pediatric Blood & Cancer|May 17, 2023
Child and family perceptions of satisfaction with neutropenia management in pediatric acute myeloid leukemiaJulia E Szymczak, Kelly D Getz, Rachel Madding, et al.
Blood|September 17, 2011
Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategiesLaura E Hogan, Julia A Meyer, Jun Yang, et al.
Leukemia & Lymphoma|November 9, 2017
Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trialsMichael J Burke, Meenakshi Devidas, Kelly Maloney, et al.
Blood Advances|September 24, 2025
Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1Kelly E Faulk, John A Kairalla, Emily Hibbitts, et al.
International Journal of Cancer|August 4, 2015
Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study AALL0331Hannah-Rose Mitchell, Xiaomin Lu, Regina M Myers, et al.
Blood|December 30, 2017
Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALLBrent Wood, David Wu, Beryl Crossley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2017
Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology GroupNaomi Winick, Meenakshi Devidas, Si Chen, et al.
Pediatric Blood & Cancer|September 20, 2025
Caregivers' Perspectives on Changes in Family Life During B-ALL Therapy: A Qualitative Study From the Children's Oncology GroupAlexandra Dreyzin, Megan Ware, Katrina Stumbras, et al.
Blood Cancer Discovery|April 14, 2026
3D chromosome remodeling in B-cell development and acute lymphoblastic leukemiaYohana E Ghebrechristos, Nikki A Evensen, Romane S Cathelin, et al.
Journal of the National Cancer Institute|May 13, 2022
Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic LeukemiaRozalyn L Rodwin, John A Kairalla, Emily Hibbitts, et al.
Pageof 7

Showing results (31-40 of 69) with videos related to

Sort By:
Pageof 7
Pediatric Blood & Cancer|May 17, 2023
Child and family perceptions of satisfaction with neutropenia management in pediatric acute myeloid leukemiaJulia E Szymczak, Kelly D Getz, Rachel Madding, et al.
Blood|September 17, 2011
Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategiesLaura E Hogan, Julia A Meyer, Jun Yang, et al.
Leukemia & Lymphoma|November 9, 2017
Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trialsMichael J Burke, Meenakshi Devidas, Kelly Maloney, et al.
Blood Advances|September 24, 2025
Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1Kelly E Faulk, John A Kairalla, Emily Hibbitts, et al.
International Journal of Cancer|August 4, 2015
Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study AALL0331Hannah-Rose Mitchell, Xiaomin Lu, Regina M Myers, et al.
Blood|December 30, 2017
Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALLBrent Wood, David Wu, Beryl Crossley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2017
Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology GroupNaomi Winick, Meenakshi Devidas, Si Chen, et al.
Pediatric Blood & Cancer|September 20, 2025
Caregivers' Perspectives on Changes in Family Life During B-ALL Therapy: A Qualitative Study From the Children's Oncology GroupAlexandra Dreyzin, Megan Ware, Katrina Stumbras, et al.
Blood Cancer Discovery|April 14, 2026
3D chromosome remodeling in B-cell development and acute lymphoblastic leukemiaYohana E Ghebrechristos, Nikki A Evensen, Romane S Cathelin, et al.
Journal of the National Cancer Institute|May 13, 2022
Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic LeukemiaRozalyn L Rodwin, John A Kairalla, Emily Hibbitts, et al.
Pageof 7